ONC
Strong BuyPremium GrowerFLAGBeOne Medicines AG · Healthcare · Switzerland · $41.5B · Avg Vol: $143M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Insufficient evidence for a screen-pass. BeOne Medicines AG: fails the quant gate on value (Q80/V25/M78; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
ABOUT BEONE MEDICINES AG
Read
BeOne Medicines AG, while not publicly traded under the provided ticker and country combination, is likely a pharmaceutical or biotechnology company focused on developing novel medical treatments. Its competitive edge would stem from proprietary research, specialized drug pipelines, and a focus on addressing unmet medical needs. This positions it as an innovative player aiming to bring new therapies to market within the healthcare sector.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.4B | 2.5B | 3.8B | 5.3B | 55.7% | 6.1B | 6.7B | 7.7B | 20.2% |
| EPS | -15.73 | -276.80 | -120.62 | -89.16 | 39.48 | — | 5.58 | 7.60 | 10.32 | -48.9% |
| Shares | — | 94.9M | 94.9M | 94.9M | 94.9M | 0.0% | 104.3M | — | — | — |
| Debt | — | 596.7M | 930.2M | 1.1B | 1.1B | 22.4% | 2.0B | — | — | — |
| Equity | — | 4.4B | 3.5B | 3.3B | 4.4B | -0.2% | — | — | — | — |
| Op CF | — | -1.5B | -1.2B | -140.6M | 1.1B | — | 1.5B | — | — | — |
| Inv CF | — | 1.1B | 60.0M | -548.4M | -276.2M | — | — | — | — | — |
| Fin CF | — | -19.0M | 416.5M | 193.4M | 1.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ONC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ONC | BeOne Medicines AG(you) | $41.5B | 87 | Strong Buy |
| BION.SW | BB Biotech AG | $3.8B | 100 | Strong Buy |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| BSLN.SW | Basilea Pharmaceutica AG | $986M | 98 | Strong Buy |
| CRSP | CRISPR Therapeutics AG | $5.6B | 20 | Sell |
| PHVS | Pharvaris N.V. | $2.5B | 21 | Sell |
| STMN.SW | Straumann Holding AG | $18.4B | 77 | Buy |
| SOON.SW | Sonova Holding AG | $17.2B | 77 | Buy |
| IDIA.SW | Idorsia Ltd | $1.7B | 21 | Sell |
| MTD | Mettler-Toledo International Inc. | $28.0B | 64 | Hold |
Peer medians: ROE 8.9% · P/E 25.5x · Gross margin 57.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.